A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A
New England Journal of Medicine 374(21): 2054-2064
Article 2016 English
Authors
FP
Flora Peyvandi
PM
Pier Mannuccio Mannucci
IG
Isabella Garagiola
Abstract
1 min read
The development of neutralizing anti–factor VIII alloantibodies (inhibitors) in patients with severe hemophilia A may depend on the concentrate used for replacement therapy.
Ilja Oomen, Marieke Verhagen, Mariarosaria Miranda, Peter Allacher, Erik A.M. Beckers, Nicole M. A. Blijlevens, Johanna G. van der Bom, Michiel Coppens, M.H.E. Driessens, Jeroen Eikenboom, Karin Fijnvandraat, Shermarke Hassan, Waander L. van Heerde, Hélène L. Hooimeijer, Joop H. Jansen, Paul Kaijen, Frank W.G. Leebeek, Daniëlle Meijer, Helmut Paul, Sanna R. Rijpma, Frits R. Rosendaal, Cees Smit, Lize F. D. van Vulpen, Jan Voorberg, Saskia E.M. Schols, Samantha C. Gouw
Discussion(0)
No comments yet. Be the first to comment.